BD-113 is under clinical development by Shanghai BDgene Therapeutics and currently in Phase II for Open-Angle Glaucoma. According to GlobalData, Phase II drugs for Open-Angle Glaucoma have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BD-113’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BD-113 overview
BD-113 is under development for the treatment of primary open-angle glaucoma (POAG) with elevated intraocular pressure and MYOC gene mutation. It is administered through intracameral route. The therapeutic candidate comprises of modified third-generation integrated defective lentivirus, that delivers gRNA and mRNA encoding Cas9 ribonucleoprotein complex (RNP) that silences the mutated MYOC gene.
Shanghai BDgene Therapeutics overview
Shanghai BDgene Therapeutics is a biotechnology company engaged in research and development of gene therapies for the treatment of genetic diseases. The company is headquartered in Shanghai City, Shanghai, China.
For a complete picture of BD-113’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
